|
Strategy & Sales |
|
Market Structure / Regulation,
Global
04 April 2019 10:45
Authors
Phil Lloyd
Head of Market Structure & Regulatory Customer Engagement
London
+44 20 7085 1271
Contributors
{{contributor-span-repeater}}
|
As we wrote in February post an FCA speech, the ‘do nothing’ strategy of waiting for fallbacks could result in market chaos.
The FSB letter in March had OSSG members ask that ISDA also consult on including an additional trigger that would take effect in the event that the FCA found LIBOR to be non-representative in its capacity as the regulator of LIBOR.
So this could bring the date in which LIBOR ends even sooner after 2021 however adds further complexity to the process of agreeing what LIBOR falls back to and more importantly at what time and how does this align with the cash market?
When / what next?
- We expect market outreach and feedback on open issues associated with the final parameters of the term and spread adjustments in Q2 2019 - Additionally in April there will be a further consultation covering the currencies such as the USD LIBOR. - It’s expected there will only be one protocol to incorporate the amended definitions for all benchmarks in Q4 2019
Ensuring the language is incorporated into the documentation is key and somewhat expected. If protocol take up is not successful and an IBOR permanently ceases to exist, the fallback would be to reference banks which, will be notoriously difficult to obtain and would just create a whole heap of uncertainty. As a result there is a sizeable risk of falling back to contractual frustration, which won’t be in either parties’ interests. The loan market has a further fallback if reference banks fail which is to lender’s cost of funds. However that is not ideal either because it will vary from lender to lender making it unlikely to reach a standard rate even within the loan market. The Bond market additionally falls back to the rate from the previous period which is far from ideal.
There seems to be a consensus view developing that the majority of outstanding LIBOR risk holders would be willing to wait for cessation triggers to activate the fallbacks in order to reduce their risk in a smooth fashion. We think it is naive to believe there will be no complications in this process and would still encourage transitioning where possible.
It’s likely that fallbacks across product classes won’t necessarily be aligned and that you could find yourself in a situation where LIBOR liquidity is significantly reduced resulting in wider bid/offer spreads in the market, negating any perceived benefit of waiting for the fallbacks. This could also potentially be catastrophic for products that are inherently connected, such as loan-linked derivatives. Aside from this, a scenario exists where Libor fixings are significantly more volatile as banks drop in and out of submission (especially if the FCA do not use the power they have to announce that a rate has become unrepresentative) leaving LIBOR holders extremely vulnerable to fixing risk, another complication that has been overlooked.
LCH have announced an intention to automatically include the ISDA IBOR fallbacks once available. If the market fails to incorporate them in bilateral transactions, the cleared and uncleared swaps market would be taking two very different positions, potentially leading to significant basis risk.
Are the cessation triggers across product classes the same?
No. The derivatives fallbacks ISDA have been working on currently only have one main trigger which is focused on the permanent cessation of an –IBOR. By contrast, in the cash market and the LMA’s replacement of screen rate language, there are a number of pre-cessation triggers.
For FRN’s and syndicated loans, the ARRC have suggested three pre-cessation triggers (LIBOR stops unannounced for five days, administrator invokes the reduced submissions policy as a number of banks no longer submit, regulator says its no longer fit for purpose etc). It clearly makes sense for there to be some kind of cohesion across product classes on what the triggers are. The FSB’s OSSG have stated the importance of this So transition now or rely on fallbacks?
While there are always other, more urgent topics to focus on, transition early to avoid market ‘chaos’ has to be the message. Having a water tight insurance contract doesn’t mean you start to drive carelessly… and of course even with a seatbelt there’s always whiplash to think about.
This is Non-Independent Research, as defined by the Financial Conduct Authority. This material should be regarded as a marketing communication and may have been produced in conjunction with the NatWest Markets Plc trading desks that trade as principal in the instruments mentioned herein. All data is accurate as of the report date, unless otherwise specified.
This communication has been prepared by NatWest Markets Plc, and should be regarded as a Marketing Communication, for which the relevant competent authority is the UK Financial Conduct Authority. Please follow the link for the following information https://www.natwestmarkets.com/natwest-markets/regulation/mar-disclosures.html
Where communicated in Singapore, this communication may be deemed an advertisement. This advertisement has not been reviewed by the Monetary Authority of Singapore.
Phil Lloyd, NWM Sales +44 2070871271 |
This material is intended for your sole use and is provided to you on the understanding that, before entering into any transaction referred to in this material, and/or any related transaction (together, the “Transaction”), you will ensure that you fully understand the potential risks and return of the Transaction and determine whether the Transaction is appropriate for you given your objectives, experience, financial and operational resources, and other relevant circumstances. Nothing in this material constitutes an offer or invitation to enter into any engagement or transaction or an offer or invitation for the sale, purchase, exchange or transfer of any securities or a recommendation to enter into any transaction, nor is it intended to form the basis of any investment decision. None of NatWest Markets Plc, NatWest Markets N.V. (and/or any branches), NatWest Markets Securities Inc. and/or their affiliates (“NatWest Markets”) is soliciting any specific action based on this material. The material does not take into account the particular investment objectives, financial conditions, or needs of individual clients or whether any transaction is suitable for any particular investor. The remuneration of the author(s) is not directly tied to any transactions performed, or trading fees received, by any entity of the NatWest Group, for example, through the use of commission-based remuneration arrangements.
This material has been prepared by NatWest Markets and has not been prepared in accordance with the legal and regulatory requirements designed to promote the independence of investment research, and is not subject to any prohibition on dealing ahead of its dissemination. Any views expressed may differ from those of other business units of NatWest Markets. The opinions, commentaries, forecasts, assumptions, estimates, derived valuations and target price(s) or other statements contained in this communication (the “Views”) are valid as at the date and/or time indicated and are subject to change at any time without prior notice. NatWest Markets does not undertake to update you of such changes. Views expressed herein are not intended to be, and should not be viewed as advice or as a personal recommendation. The Views may not be objective or independent of the interests of the authors or other NatWest Markets trading desks, who may be active participants in the markets, investments or strategies referred to in this material. NatWest Markets will not act and has not acted as your legal, tax, regulatory, accounting or investment adviser; nor does NatWest Markets owe any fiduciary duties to you in connection with the Transaction and no reliance may be placed on NatWest Markets for investment advice or recommendations of any sort. You should make your own independent evaluation of the relevance and adequacy of the information contained in this document and make such other investigations as you deem necessary including obtaining independent financial advice, before participating in any transaction in relation to the securities referred to in this document. This material is not intended for distribution to, or use by any person or entity in any jurisdiction or country where such distribution or use would be contrary to local law or regulation. The information contained herein is confidential and may not be given (in whole or part) or otherwise distributed to any other third party without the prior written consent of NatWest Markets.
NatWest Markets and its affiliates, connected companies, employees or clients may have an interest in financial instruments of the type described in this material and/or in related financial instruments giving rise to potential conflicts of interest which may impact the performance of such financial instruments. Such interests may include, but are not limited to, (a) dealing in, trading, holding or acting as market-maker or liquidity provider in such financial instruments and any reference obligations; (b) entering into hedging strategies on behalf of issuer clients and their affiliates, investor clients or for itself or its affiliates and connected companies; and (c) providing banking, credit and other financial services to any company or issuer of securities or financial instruments referred to herein. NatWest Markets and its affiliates, connected companies, employees or clients may at any time acquire, hold or dispose of long or short positions (including hedging and trading positions) which may impact the performance of a financial instrument.
This material may relate to over-the-counter derivatives (“OTC Derivatives”) in which case you should be aware that OTC Derivatives can provide benefits but may also involve a variety of significant risks. All OTC Derivatives involve risks which include (among other things) the risk of adverse or unanticipated market, financial or political developments, risks relating to the counterparty, liquidity and other risks of a complex character. In the event that such risks arise, substantial costs and/or losses may be incurred and operational risks may arise in the event that appropriate internal systems and controls are not in place. Therefore you should also determine whether OTC Derivatives are appropriate for you given your objectives, experience, financial and operational resources, and other relevant circumstances.
If you enter into an OTC Derivative transaction and decide to close out the transaction, or the transaction otherwise terminates before its scheduled termination date, you may have to pay break costs. These will be calculated by reference to prevailing market conditions and include any costs incurred by NatWest Markets in terminating any related financial instrument or trading position. Please note that such break costs can be substantial. If you enter into an OTC Derivative transaction for the purposes of hedging a loan or other debt and you subsequently wish to repay the debt (whether through refinancing or otherwise), you should be aware that it may be necessary for NatWest Markets to terminate the hedging transaction before its scheduled termination date and satisfy any liabilities that you may have to it with respect to such transaction (including break costs) before NatWest Markets will release any related security that you have provided to it.
This material has been prepared for information purposes only, does not constitute an analysis of all potentially material issues and is subject to change at any time without prior notice. NatWest Markets does not undertake to update you of such changes. It is indicative only and is not binding. Other than as indicated, this document has been prepared on the basis of publicly available information believed to be reliable but no representation, warranty, undertaking or assurance of any kind, express or implied, is made as to the adequacy, accuracy, completeness or reasonableness of this material, nor does NatWest Markets accept any obligation to any recipient to update, correct or determine the reasonableness of such information or assumptions contained herein. NatWest Markets and each of its respective affiliates accepts no liability whatsoever for any direct, indirect or consequential losses (in contract, tort or otherwise) arising from the use of this material or reliance on the information contained herein. However this shall not restrict, exclude or limit any duty or liability to any person under any applicable laws or regulations of any jurisdiction which may not lawfully be disclaimed.
In the U.S., this material, to the extent it relates to securities, is intended for distribution only to major institutional investors as defined in Rule 15a-6 of the U.S. Securities Exchange Act of 1934 as amended (excluding documents produced by our affiliates within the U.S. which are subject to the following disclaimer https://www.agilemarkets.com/api/ds/v1/d isclaimer/publication/2756). This material is not intended as an offer or the solicitation of an offer to buy or sell securities as defined under U.S. securities laws.
Notwithstanding the foregoing (but subject to any applicable federal or state securities laws), NatWest Markets and the recipient may disclose to any and all persons, without limitation, the tax treatment and tax structure of any transaction contemplated hereby and all materials (including opinions or other tax analyses) relating thereto. IRS Circular 230 Disclosure: NatWest Markets does not provide tax advice. Accordingly, any discussion of U.S. tax matters contained herein (including any attachments) is not intended or written to be used, and cannot be used, in connection with the promotion, marketing or recommendation by anyone unaffiliated with NatWest Markets of any of the matters addressed herein or for the purpose of avoiding U.S. tax-related penalties.
NatWest Markets Plc is authorised by the Prudential Regulation Authority and regulated by the Financial Conduct Authority and Prudential Regulation Authority and is provisionally registered as a swap dealer with the United States Commodity Futures Commission. NatWest Markets N.V. is incorporated with limited liability in the Netherlands, authorised by De Nederlandsche Bank and regulated by De Nederlandsche Bank and the Autoriteit Financiële Markten. It has its seat at Amsterdam, the Netherlands, and is registered in the Commercial Register under number 33002587. Registered Office: Claude Debussylaan 94, Amsterdam, the Netherlands. Branch Reg No. in England BR001029. Agency agreements exist between different members of NatWest Group. Securities business in the United States is conducted through NatWest Markets Securities Inc., a FINRA registered broker-dealer (http://www.finra.org), a SIPC member (www.sipc.org) and a wholly owned indirect subsidiary of NatWest Markets Plc. NatWest Markets Securities Inc. is authorised by NatWest Markets Plc to act as its agent for certain kinds of its activities.
Copyright © NatWest Markets Plc. All rights reserved.